AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01605734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.
Study NCT01605734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib combined with TACE
Description: All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
Study NCT05231564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid training
Description: The experimental group trained two to three sessions of 45 to 50 minutes a week with a recovery of 24 to 48 hours between each session to burn 500 kcal. The first three weeks held hybrid training with a metabolic program and the other three weeks held a strength training program.
Study NCT02190760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02190760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT03841981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric and physical examination
Description: * Weight and height.~* Waist-to-hip ratio.~* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].
Study NCT03841981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry, accelerometer and seven-day dietary recall
Description: Energy availability assessment.
Study NCT02261857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized continuous positive airway pressure (CPAP) mask
Description: Personalized CPAP mask manufactured for study subjects using a combination of patient-specific computer-aided design and three-dimensional printing
Study NCT01530880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ibuprofen
Description: Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
Study NCT01530880 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen (Standard of Care)
Description: Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
Study NCT04444479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECG verification
Description: The correct positioning of the PICC catheter tip will be verified using ECG.
Study NCT04444479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: X-ray verification
Description: The correct positioning of the PICC catheter tip will be verified using X-ray imaging.
Study NCT04123769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone
Description: First take Hydronidone capsule, single-dose and then Multiple-dose
Study NCT00651586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% ophthalmic solution
Description: Gatifloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
Study NCT02580734 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: Cross-over randomized clinical trials
Study NCT02580734 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: melatonin
Description: Cross-over randomized clinical trials
Study NCT00956826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agit Vacuum
Description: With an electrode and a regular vacuum device
Study NCT03122626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Together in Movement and Exercise (TIME) Program
Description: The TIME program is an evidence-based, standardized, progressive, licensed exercise program developed by physical therapists at the Toronto Rehabilitation Institute-University Health Network.
Study NCT00112476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV
Study NCT00112476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT05888025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Delivered Mindfulness-based Cognitive Therapy (MBCT-T)
Description: MBCT-T will be delivered in groups of four to eight subjects by telephone using a conference line with NYULH WebEx. Participants will receive a workbook containing session content and home practice logs and audio guides for home practice. Subjects will complete individual orientation sessions with the MBCT-T facilitator prior to start of the group sessions. The four subsequent weekly group sessions are approximately 90 minutes long. Participants will be encouraged to practice daily meditation in between group sessions for 20-30 minutes, six days per week
Study NCT05218811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation Assisted Partial Nephrectomy
Description: Cryoablation Assisted Partial Nephrectomy is monitored under Ultrasound guidance, A Cryoablation machine (FDA Approved Device) along with its Cryoprobes are used in the study The Cryoprobes are placed in close to the endophytic tumor margins. The tumor boundary area will undergo one freezing cycles. Tumor is excised after 5 minutes of freezing cycle. Thawing process is passive, renal defect repair is conducted during thawing process.
Study NCT02779205 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: adipose tissue sample
Description: adipose tissue sample
Study NCT00812669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Study NCT00812669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00812669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00812669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00812669 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Study NCT00812669 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Study NCT00812669 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00812669 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Study NCT00812669 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study NCT00812669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study NCT00812669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT02872103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
Study NCT02872103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: F-627
Description: F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
Study NCT02872103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
Study NCT03617926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X92001666
Description: the X92001666 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
Study NCT03617926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RID shampoo
Description: Active Comparator: RID shampoo The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
Study NCT00651586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 0.3% ophthalmic solution
Description: Ciprofloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
Study NCT02753959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intervention
Description: Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~* Electrical impedance tomography (EIT)~* EMGpara~* SpO2~* tcCO2~* Respiratory inductance plethysmography~* EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~* Manual techniques only~* MIE at low pressure (+30 to -30)~* MIE at high pressure (+60 to -60)
Study NCT02753959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable Intervention
Description: Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~* Electrical impedance tomography (EIT)~* EMGpara~* SpO2~* tcCO2~* Respiratory inductance plethysmography~* EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~* Manual techniques only~* MIE at low pressure (+30 to -30)~* MIE at high pressure (+60 to -60)
Study NCT05093491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry and ultrasonography in stroke group
Description: Ultrasonographic measurements were performed of the bilateral diaphragm and abdominal muscle thickness and thickening ratio in the supine position in the stroke patient group. The spirometric evaluation was also performed
Study NCT05093491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry and ultrasonography in healthy group
Description: Ultrasonographic measurements were performed of dominant side diaphragm and abdominal muscle thickness and thickening ratio in the supine position in healthy individuals group. The spirometric evaluation was also performed
Study NCT00747162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measure of muscle oxygenation
Description: The investigators will use an INVOS oxymeter for muscle oxygenation measure.
Study NCT00747162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin pigmentation determination
Description: The investigators will use a DermaSpectrometer to get a reading from subjects' skin color
Study NCT02344732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily
Study NCT02344732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily
Study NCT02344732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homatropine 2% eye drops thrice daily
Study NCT01994187 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Study NCT01994187 — intervention group
Intervention type: PROCEDURE
Intervention: carotid angioplasty
Study NCT04407715 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: The Effect Of Minimal and High Flow Anesthesia on Optic Nerve Sheath Diamater
Description: The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow.
Study NCT04407715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Effect Of Minimal and High Flow Anesthesia on Optic Nerve Sheath Diamater
Description: The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow.
Study NCT04251494 — intervention group
Intervention type: OTHER
Intervention: Routine blood samples
Description: Blood samples will be taken from participants during their outpatient appointment. Patients routinely have blood samples taken during this clinic. The study will use the results from the routine blood tests, and also extra blood samples to collect data on other biomarkers. The laboratory facilities at Guy's and St Thomas Hospitals will be used to conduct analysis, no other laboratories will be used. Data will be collected on Phenylalanine levels, lipids, vitamin B12 and related biomarkers.
Study NCT03567187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iovera
Description: The iovera° device is 510(k)-cleared (K133453 and K161835) and is used to form a precisely controlled, sub-dermal cold zone of -20 to -88.5 degrees Celsius to temporarily disrupt peripheral nerve function, ultimately blocking pain. It is not indicated for the treatment of central nervous system tissue.
Study NCT02834130 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Evaluation of psychological and psychopathological
Study NCT02844855 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive tests
Description: MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
Study NCT02844855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive tests
Description: MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
Study NCT03390660 — intervention group
Intervention type: OTHER
Intervention: WIC program participation
Description: WIC program is a welfare program in the U.S. to provide nutritional supplements to low-income women, infants, and children.
Study NCT06544590 — intervention group
Intervention type: DEVICE
Intervention: taVNS
Description: TaVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms \[18,28\]. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. In the taVNS group received 12 weeks of treatment (30 min each time, once daily, 5 times per week).
Study NCT02510807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: The use of a pedometer will demonstrate improvement in the following health outcomes in patients with PAD by acting as a method of surveillance to improve compliance with a walking regimen
Study NCT01485874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil (Pegylated Liposomal Doxorubicin)
Description: Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle
Study NCT01485874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle
Study NCT00310310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Apnea Self-Management Program
Description: Sleep apnea self-management program - 4 sessions, group-based.
Study NCT06544590 — intervention group
Intervention type: DRUG
Intervention: Betahistine Mesylate tablet
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
Study NCT00310310 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual sleep apnea and cpap care
Study NCT01021007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine
Description: Rinse 2 times per day for 6 weeks
Study NCT01021007 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: Use 2 times per day for 6 weeks
Study NCT00870688 — intervention group
Intervention type: DRUG
Intervention: sodium valproate
Description: valproate sustained release minitablets, once daily.
Study NCT03619213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg tablets given once daily, per oral use.
Study NCT03619213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching dapagliflozin 10 mg
Study NCT04106388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Behavioral Health Integration
Description: The virtual behavioral health integration program, implemented in primary care settings, is a structured mental illness treatment program that includes both behavioral treatment and counseling components aimed at reducing cost of care, developing and sustaining adaptive coping strategies, and improving short term acute care utilization.
Study NCT04337437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab
Description: 150 mg/1ml/bottle, single subcutaneous injection.
Study NCT04337437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for this trial
Description: The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
Study NCT04463706 — intervention group
Intervention type: OTHER
Intervention: Predictors adverse evolution
Description: Predictors adverse evolution in all hospital participant admitted patients
Study NCT04463706 — intervention group
Intervention type: OTHER
Intervention: Predictors of health care provide
Description: Predictors of death, unequity, variability in process of care, cost in all COVID positive patients form the Basque Country
Study NCT00893620 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft
Description: These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
Study NCT01449643 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold
Study NCT01564407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICX-RHY-013
Description: Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~1. Empty control no injection~2. Vehicle only (0.5 ml of HypoThermosol solution)~3. 5 million cells / cm² , single administration at Day 0~4. 5 million cells/ cm² , single administration at week 4~5. 5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks
Study NCT01564407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICX-RHY-013
Description: Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~1. Empty control no injection~2. Vehicle only (0.5 ml of HypoThermosol solution)~3. 5 million cells / cm² , single administration at Day 0~4. 5 million cells/ cm² , single administration at week 4~5. 5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks
Study NCT04755556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: home based intensive bimanual training
Description: Home Based Intensive Bimanual Training with Routine Physical Therapy bimanual training includes. functional activities play with ball, make a dough, make beads, make blocks .Routine Physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
Study NCT04755556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Physical Therapy
Description: Routine physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.